We will feature stories from our Young Investigator Awardees, genetic counselors, and leaders in the field of BRCA research and outreach. Our awardees will discuss their very own cutting-edge research that aims to prevent, diagnose, and cure BRCA cancers as early as possible.
The findings, a meta-analysis of 44 existing peer-reviewed studies, are published in the Journal of the National Cancer Institute. The analysis also helped better define factors that may increase risk among this population: Smoking, for instance, may raise the risk of breast cancer for patients with a BRCA2 mutation.
Though the team cautions that more data are required before definitive conclusions about these variables can be made, the findings help to shed light on non-surgical risk reduction options for women who may not be ready to undergo prophylactic removal of their ovaries to cut their cancer risk.
A woman's risk of developing breast or ovarian cancer is notably increased if she inherits a harmful mutation in either the BRCA1 gene or the BRCA2 gene from either parent.
Fifty-five to 65 percent of women who inherit a harmful BRCA1 mutation, and about 45 percent of women who inherit a harmful BRCA2 mutation will develop breast cancer by age 70, compared to approximately 12 percent of women in the general population.
Thirty-nine percent of women who inherit a harmful BRCA1 mutation and up to 17 percent of women who inherit a harmful BRCA2 mutation will develop ovarian cancer by age 70, compared to only 1. Both BRCA mutations have also been associated with increased risks of several other types of cancer.
Though the study's findings point to a helpful role for birth control pills in cutting ovarian cancer risk, the relationship between oral contraceptives and breast cancer risk was ambiguous. The authors say women and their health care providers should weigh the potential benefits of oral contraceptives reduction in ovarian cancer risk, avoidance of unintended pregnancy, and regulation of menstrual cycles, for instance against the potential risks such as blood clots or the possible increased risk of breast cancer.
There was also insufficient evidence to draw conclusions about the relationships between breastfeeding and tubal ligation, respectively, and breast cancer.
Future research aims to examine these issues as well as how other variables, such as alcohol consumption, affect the risk of breast and ovarian cancer for BRCA mutation carriers. Friebel, MPH, is also an author of the paper. The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.
Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.A team led by Walter and Eliza Hall Institute researchers found that ovarian tumors with complete BRCA1 methylation and silencing were more susceptible to treatment. Mutation screening of the breast cancer genes BRCA1 and BRCA2 identifies a large fraction of variants of uncertain clinical significance (VUS) whose functional and clinical interpretations pose a challenge for genomic medicine.
The BRCA Journal is pleased to announce the launch of its "Innovative Guest" series.
We will feature stories from our Young Investigator Awardees, genetic counselors, and leaders in the field of BRCA research and outreach. A paper describing the research will be published May 10 in JAMA Oncology.
Kurian is the lead author. Kurian is the lead author. Steven Katz, MD, MPH, professor of medicine and of health management and policy at the University of Michigan, is the senior author.
Complete sequence analysis of BRCA1 and BRCA2 genes was performed through Next Generation Sequencing technology using ION Torrent TM Oncomine TM BRCA Research Assay (Life Technologies).
Manual libraries preparation was generated from 20 ng of DNA per sample according to the manufacturer’s instructions with barcode incorporation.
INTRODUCTION—Science's special section on breast cancer takes a look at the state of research and treatment 20 years after the isolation of the BRCA1 gene. [Read the full introduction].